Allogene Therapeutics CEO David Chang receives $13M in 2018
Allogene Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 24, 2019
Allogene Therapeutics reported fiscal year 2018 executive compensation information on April 24, 2019.
In 2018, four executives at Allogene Therapeutics received on average a compensation package of $5.2M.
Average pay of disclosed executives at Allogene Therapeutics
David Chang, Chief Executive Officer, received $13M in total. 70% of Chang's compensation, or $8.9M, was in stock awards. Chang also received $218K in non-equity incentive plan, $3.1M in option awards, $362K in salary, as well as $250K in other compensation.
Joshua Kazam, Former President, received a compensation package of $3.6M. 100% of the compensation package, or $3.6M, was in stock awards.
Eric Schmidt, Chief Financial Officer, earned $2.6M in 2018.
Alison Moore, Chief Technical Officer, received $1.8M in 2018.
Related executives
You may also like
Source: SEC filing on April 24, 2019.